Rapid Medical Receives Funding to Advance Commercialization of Stroke Treatment Devices

 

July 17, 2017—Rapid Medical, an Israel-based company focused on the development of neurovascular interventional devices, announced that it has completed a Series B financing of $9 million to advance the commercialization of the company's minimally invasive stroke treatment and prevention products, the Tigertriever revascularization device and the Comaneci adjustable remodeling mesh. The round was led by BRM group from Israel and Shanghai-Israel Investment Fund from China, with participation from Winnovation and Gefen Capital.

The funding will support regulatory clearance in the United States, as well as continuing to advance the European commercialization of both devices. Specifically, the funding will support initiation of the company's TIGER clinical trial, which will begin enrolling patients in the first half of 2018 at selected leading centers in the United States, Europe, and Israel.

According to Rapid Medical, Tigertriever is a controllable, fully visible stentriever that can be adjusted by the physician to fit the dimensions of blocked blood vessels that cause acute ischemic stroke. Comaneci is a controllable, fully visible aneurysm neck–bridging mesh device that does not require parent vessel occlusion. It is intended to provide temporary assistance for embolization of intracranial aneurysms.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.